shortagewatch

Home / Companies / Recordati

Company family · HQ IT

Recordati: medicine shortages

REC · Borsa Italiana

As of 2 Nov 2026, 8 Recordati products have a reported shortage across 5 countries, covering 6 medicines.

Products short8rank #220 of 464
Medicines6active ingredients
Countries5/16
New in 90 days3+3 vs market pace
Typical duration12 monthsmedian so far
Manufacturing29%demand-driven 0%

Where

Germany2Italy3Spain1Czechia1Norway1

Which therapeutic classes

Digestive tract and metabolism2Nervous system2Musculoskeletal system1Dermatologicals1Cardiovascular system1Cancer and immune system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
RecordatiRecordati: Manufacturing problem 2 (25%)25%Recordati: Distribution or logistics 1 (12%)12%Recordati: Commercial decision or withdrawal 2 (25%)25%Recordati: Other 2 (25%)25%Recordati: Not stated 1 (12%)12%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

00112Dec: 0Jan ’25: 1Feb: 0FebMar: 0Apr: 0May: 1MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 2NovDec: 0Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 0AugSep: 1Oct: 2Nov: 0Nov

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Recordati8

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Recordati: 8 / 6Recordati

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Bupivacaine26 Jan 2025Commercial decision or withdrawal8/16
Mesalazine25 Nov 2025Other11/16
Diclofenac17 May 2025Manufacturing problem3/16
Fenticonazole122 Oct 2026Not stated1/16
Lercanidipine121 Sep 2026Distribution or logistics4/16
Leuprorelin129 Oct 2026Manufacturing problem5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.